Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on Schisandra chinensis and related compounds. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before taking any supplement, particularly if you use medications, have liver disease, or are pregnant or nursing.

The search usually starts with Kampo. Someone finds a reference to 五味子 in a Japanese health article, a bottle of schisandra berry extract on Amazon, or an ingredient list on an adaptogen blend — and the questions that follow are practical: what is this berry, why does Japan’s traditional medicine system treat it as significant, and does the liver protection claim have real science behind it or only centuries of tradition?

That last question has an honest two-part answer. The evidence on schisandrin lignans — the primary bioactive compounds in Gomishi — is genuinely interesting and mechanistically coherent. It is also predominantly animal and cell-based. The human clinical trial record for schisandra as an isolated supplement is thin and has not confirmed the animal findings at the scale that would allow outcome claims. Both parts of that picture belong in the same sentence.

What Gomishi is and how Kampo uses it

五味子 (Gomishi) is the Japanese pharmacopoeia name for the dried ripe fruits of Schisandra chinensis — a woody vine native to northeastern China, the Korean Peninsula, and the Russian Far East, cultivated in Japan as well. The name translates as “five-flavor fruit,” a reference to the classical East Asian medical belief that this berry simultaneously expresses all five taste categories recognized in the system: sour, sweet, salty, bitter, and pungent. In practice, the taste is predominantly sour with secondary sweetness; the “five-flavor” designation reflects a pharmacological classification rather than a culinary one.

Gomishi has been part of the Japanese Kampo (漢方) system for centuries. Kampo developed in Japan from classical Chinese medicine imported during the 7th through 10th centuries and was progressively adapted to Japanese clinical practice, local epidemic patterns, and available botanicals. By the Edo period, Kampo had established its own canonical formulas, diagnostic framework, and practitioner tradition — distinct from the contemporaneous Chinese medicine it descended from. In the modern regulatory framework, Kampo formulas in Japan are classified as pharmaceutical products, not supplements, and are manufactured to pharmacopoeia-compliant specifications.

In Kampo classification, Gomishi serves primarily as a hojo-nin (補腎) herb — a category associated with supporting what Kampo calls the kidney organ system, a conceptual grouping that encompasses adrenal, reproductive, and aging-related physiology rather than the anatomical kidney of Western biomedicine. Classical Kampo applications include fatigue recovery, night sweats, spontaneous perspiration, chronic cough with frailty, and general tonification in elderly patients.

That clinical tradition carries into Japan’s OTC Kampo market today. Tsumura and Kracie — the two leading manufacturers of regulated OTC Kampo preparations in Japan — include Gomishi in several approved compound formulas. These products are manufactured to Japanese Pharmacopoeia specifications for Gomishi raw material, a quality benchmark substantially different from the unregulated supplement market in the US and Europe. This does not mean that a consumer Tsumura formula is equivalent to taking a schisandra extract capsule for any particular purpose — Kampo formulas are multi-herb compositions prescribed against pattern diagnoses, not single-herb supplements — but it establishes that Gomishi operates within a well-characterized pharmaceutical-grade supply chain in Japan, not purely the wellness supplement space.

Schisandrins: the lignan compounds and what they are

The primary bioactive compounds in Schisandra chinensis are dibenzocyclooctadiene lignans — a class of polyphenolic compounds that accumulates at high concentrations in the berry’s seeds and fruit pulp. The seeds are particularly lignan-dense; seed-derived extracts typically deliver higher concentrations than whole-fruit powders. Principal lignans studied in the research literature include:

• Schisandrin B (also called γ-schisandrin or gomishin B): the most extensively studied individual compound, primarily in the context of liver enzyme modulation and antioxidant activity
• Schisandrin A (α-schisandrin / deoxyschisandrin): studied alongside schisandrin B; some research interest for cardiac and anti-fatigue contexts
• Gomisin A (schisandrol B): additional lignan with documented in vitro liver cell protection data
• Schisandrin C and related minor lignans present in varying proportions depending on extraction method

The lignan profile of any given product depends on sourcing (which plant parts), solvent extraction methods, and standardization. Products stating “standardized to X% schisandrins” most often refer to total lignan content; those specifying schisandrin B individually offer a more precise benchmark for comparing against research protocols.

What the evidence shows — and where it runs thin

The calibration required here is specific to the evidence category: hepatoprotective effects are well-documented in animal and cell research; translation to confirmed human clinical outcomes has not followed at the same depth.

Liver enzyme support: the animal and in vitro record

Schisandrin B has been studied in rodent models of chemically induced liver injury — carbon tetrachloride hepatotoxicity is a standard experimental model — where it has shown dose-dependent attenuation of liver enzyme elevation (ALT, AST) and oxidative stress markers across numerous published studies, primarily from Chinese and Taiwanese research groups working from the 1990s onward. A well-cited mechanistic framework connects schisandrin B’s hepatic effects to activation of the Nrf2/antioxidant response element pathway, which upregulates endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase) and provides mitochondrial protection under oxidative stress conditions. Reviews of the hepatoprotection animal literature have consistently found reproducible protective effects across multiple model systems.

In human-derived liver cell lines (HepG2 cells and primary hepatocytes), schisandrin compounds have shown reduced cytotoxicity from various chemical stressors, primarily through the same antioxidant pathway activation documented in animal models.

What the human trial record contains: limited. A small uncontrolled pilot study examined Schisandra extract over 24 weeks in subjects with elevated liver enzymes and reported reductions in ALT; without a control group, isolating the Schisandra effect from spontaneous liver enzyme fluctuation is not possible. Several Chinese clinical trials have evaluated Schisandra-containing compound formulas in liver disease contexts, but multi-herb formulas make it impossible to isolate the Schisandra contribution specifically.

Calibrated position: Schisandra lignans may support healthy liver enzyme levels based on consistent animal research and a mechanistically coherent pathway. Confirming this effect in humans at supplement doses with a placebo-controlled trial design has not been done to an adequate scale. The phrase “may support liver health” is the honest framing; “hepatoprotective” as an outcome claim in humans remains ahead of the evidence.

Adaptogen and anti-fatigue research

Schisandra is consistently classified as an adaptogen — a pharmacological category developed by Soviet researchers in the 1940s and 1950s to describe substances associated with nonspecific resistance to physical and psychological stressors. The Soviet research tradition studied Schisandra alongside Eleutherococcus senticosus (Siberian ginseng) and Rhodiola rosea in the context of cold-weather military and athletic performance optimization. Methodological standards in these studies vary considerably from current RCT criteria.

A systematic review by Panossian and Wikman, published in the Journal of Ethnopharmacology, examined the adaptogen evidence base including Schisandra and found that anti-fatigue and stress-resistance properties were supported by substantial preclinical pharmacology alongside a limited and methodologically variable human clinical base. Proposed mechanisms include cortisol pathway modulation, Nrf2 antioxidant activation, and effects on nitric oxide signaling related to cardiovascular stress response.

Several more recent randomized crossover trials in healthy adults have examined Schisandra extract against placebo on fatigue and exercise performance endpoints; results have generally shown modest reductions in subjective fatigue and improved endurance markers in the Schisandra arms. Sample sizes in these trials are small, and between-group differences relative to variability do not yet constitute a strong evidence base.

Calibrated position: Schisandra is associated with reduced fatigue perception and improved stress adaptation in preliminary research, with a coherent mechanistic picture. The human RCT base is limited. “May support stress resilience and reduce fatigue” is supportable at preliminary evidence level — not as an established clinical finding.

Cognitive function: preliminary signals

A small number of trials have examined Schisandra’s effects on attention and working memory. A double-blind, placebo-controlled trial published in Phytomedicine by Aslanyan et al. evaluated schisandra extract in subjects reporting mental fatigue and found improvements in attention and accuracy on a task battery over a multi-week period. The trial was small and has not been independently replicated at scale. This is a preliminary signal worth noting, not a basis for cognitive enhancement claims.

Why the Kampo framing matters for buyers

Positioning Gomishi within Kampo — rather than purely as an adaptogen supplement from generic botanical sourcing — matters for three reasons.

First, quality. Japan’s Pharmacopoeia Gomishi monograph specifies morphological, microscopic, and compositional standards for the dried fruit. Tsumura and Kracie source Gomishi to these specifications as pharmaceutical inputs. The international supplement market does not operate to this standard by default; third-party testing certificates from NSF, USP, or equivalent bodies approximate it.

Second, context of use. Kampo practitioners prescribe formulas containing Gomishi as part of pattern-matched treatment approaches that consider the patient’s full presentation. The Gomishi dose, accompanying herbs, and clinical rationale are all part of that framework. Taking a schisandra extract capsule is not equivalent to Kampo treatment — it is one isolated component used out of its clinical context.

Third, the “evidence and tradition intersect” framing that Choju Lab applies to Japanese longevity ingredients is particularly apt here. Gomishi is unusual in that it has both centuries of clinical use within a regulated Japanese pharmaceutical tradition and a genuinely active preclinical research base that has worked to characterize its mechanisms at the molecular level. That combination is rarer in the adaptogen category than marketing copy suggests.

Side effects and interactions

CYP3A4 and P-glycoprotein inhibition: schisandrin compounds are documented inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in pharmacokinetic research. Both are important drug metabolism and efflux mechanisms. P-gp inhibition can increase plasma concentrations of P-gp substrate drugs; CYP3A4 inhibition affects metabolism of a wide range of pharmaceuticals including immunosuppressants (cyclosporine, tacrolimus), certain statins, some anticoagulants, and various cardiovascular medications. The P-gp inhibition in particular has been documented at doses relevant to commercial supplement servings in multiple animal pharmacokinetic studies. This interaction risk is concrete, not theoretical. Anyone on immunosuppressant therapy, narrow-therapeutic-window medications, or CYP3A4-sensitive pharmaceuticals should discuss Schisandra supplementation with their prescribing physician or pharmacist before starting.

Pregnancy: Schisandra has traditional use in some East Asian contexts as a labor-related herb, suggesting possible uterotonic activity. Schisandra supplementation during pregnancy is not recommended without specific medical guidance.

Liver disease: paradoxically, individuals with diagnosed liver disease should approach Schisandra with caution — the lignan compounds are hepatically metabolized, and how impaired hepatic function affects their processing and potential accumulation is not characterized in controlled studies. Consult a hepatologist.

General adverse effects at typical supplement doses: reported effects in human trials include mild gastrointestinal discomfort, decreased appetite, and isolated reports of skin reactions. Some animal studies suggest dose-dependent central nervous system sedation, though whether this occurs at human supplement doses is not established.

How to buy schisandra / Gomishi supplements

Three formats dominate the market:

Standardized extract capsules: the format most relevant for potency transparency. Look for products specifying schisandrin content — typically 1–2% by weight, from fruit or seed extraction. Seed-based extracts deliver higher lignan concentrations. Specifying schisandrin B as the standardization marker provides a more precise benchmark than total schisandrin percentage. Third-party testing certificates (NSF, USP, Informed Sport) verify label accuracy. Schisandra berry extract capsules standardized for schisandrins from established supplement brands are available; filtering for schisandrin B specification narrows the quality range usefully.

Dried berry powder: less concentrated than extract, closer to traditional dietary preparation context. For those interested in starting with a more conservative dose approach, schisandra five-flavor berry powder allows flexible serving adjustment and avoids extract concentration.

Schisandrin B-specific products: some brands now offer products standardized specifically to schisandrin B, reflecting the research focus on this particular lignan. Schisandrin B supplement searches surface these options. Whether isolating a single lignan outperforms a full-spectrum fruit extract at equivalent schisandrin B dose has not been tested in human trials.

Commercial servings across capsule products run 500–2,000 mg of dried berry equivalent. There is no established effective dose from human RCTs because the adequately powered controlled trials have not been conducted; these dosing conventions reflect traditional use patterns and market convention rather than clinical dose-response data.

Who should not take Schisandra / Gomishi without physician guidance

• Anyone on immunosuppressant medications, particularly cyclosporine or tacrolimus — P-gp inhibition risk is documented in pharmacokinetic studies and is not speculative
• Anyone taking CYP3A4-sensitive medications including certain statins, calcium channel blockers, and cardiovascular drugs — verify with your pharmacist before starting
• Pregnant or nursing women
• Individuals with diagnosed liver disease — consult a hepatologist before adding any hepatically metabolized supplement
• Anyone on anticoagulant therapy
• Individuals already supplementing with multiple adaptogens — combination effect profiles with Schisandra are not characterized

For people primarily drawn to the liver support angle: Schisandra is a legitimate subject of ongoing hepatoprotection research with genuine mechanistic depth. It is not a substitute for hepatologist evaluation of elevated liver enzymes, and the human trial evidence for clinical liver outcomes has not reached the threshold that would support a clinical recommendation. Engage with it as a research-stage ingredient with a strong preclinical track record.

For people approaching Schisandra through the adaptogen and fatigue reduction frame: the evidence base is comparable to Rhodiola rosea in terms of evidence maturity — substantial Soviet and Asian preclinical and clinical research tradition, a limited but growing modern RCT base, and mechanistic coherence without confirmed clinical outcome data in healthy adults. The Kampo tradition adds a layer of structured clinical use context that most adaptogen marketing lacks, while not substituting for the controlled trial evidence that would support confident recommendation.

---

See also: Ashitaba and autophagy: what the chalcone research shows, Berberine and Kampo’s ōbaku connection, Japanese medicinal mushroom research: ergothioneine and cytoprotection.